We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

10 hedge funds and large institutions have $50M invested in Altamira Therapeutics Ltd in 2015 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more capital invested

Capital invested by funds: $41M → $50M (+$9.06M)

0% more funds holding

Funds holding: 10 → 10 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
10
Holders Change
–
Holders Change %
0%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WA
Wasatch Advisors
Utah
+$576K
2
KeyBank National Association
KeyBank National Association
Ohio
+$288K
3
OM
Opaleye Management
Massachusetts
+$288K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tekla Capital Management
Massachusetts
-$2.88M
2
RCM
RA Capital Management
Massachusetts
-$1.67M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$288K
4
Goldman Sachs
Goldman Sachs
New York
-$60K
5
TRCT
Tower Research Capital (TRC)
New York
-$31K
Name Holding Trade Value Shares
Change 		Change in
Stake
WA
1
Wasatch Advisors
Utah
$13.6M +$576K +2 +6%
BAMS
2
Bellevue Asset Management (Switzerland)
Switzerland
$10.4M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$8.15M – – –
CPCM
4
Clifton Park Capital Management
Delaware
$7.6M – – –
TCM
5
Tekla Capital Management
Massachusetts
$6.2M -$2.88M -10 -38%
OM
6
Opaleye Management
Massachusetts
$1.83M +$288K +1 +25%
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$1.02M -$288K -1 -25%
TAM
8
Tocqueville Asset Management
New York
$489K – – –
HCM
9
Harvey Capital Management
Florida
$251K – – –
KeyBank National Association
10
KeyBank National Association
Ohio
$214K +$288K +1 New
Morgan Stanley
11
Morgan Stanley
New York
$59K – – –
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$59K – – –
VKH
13
Virtu KCG Holdings
New York
$49K – – –
MLM
14
Mount Lucas Management
Pennsylvania
$15K – – –
UBS Group
15
UBS Group
Switzerland
$7K – – –
Deutsche Bank
16
Deutsche Bank
Germany
$4K – – –
RCM
17
RA Capital Management
Massachusetts
– -$1.67M -6 Closed
Goldman Sachs
18
Goldman Sachs
New York
– -$60K – –
TRCT
19
Tower Research Capital (TRC)
New York
– -$31K – –
Walleye Trading
20
Walleye Trading
New York
– -$1K – –
Wells Fargo
21
Wells Fargo
California
– -$1K – –

CYTO Hedge Fund Activity: Q4 2015 in Review

10 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2015, worth a combined $50M — up 22% from $41M a quarter earlier.

Fund positioning in CYTO was balanced in Q4 2015: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 2 trimmed.

The largest buyer was Wasatch Advisors, adding an estimated $576K. The largest seller was Tekla Capital Management, cutting an estimated $2.88M.

  • 10 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2015, unchanged from Q3 2015.
  • Funds reported $50M of Altamira Therapeutics Ltd stock for Q4 2015, up 22% quarter-over-quarter.
  • 1 fund opened new Altamira Therapeutics Ltd positions in Q4 2015 and 1 closed out, a net change of 0 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q4 2015 was Wasatch Advisors, an estimated $576K added.
  • The largest Altamira Therapeutics Ltd seller in Q4 2015 was Tekla Capital Management, an estimated $2.88M sold.

Based on aggregated 13F filings for Q4 2015.